Nasdaq

Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination ...

--Astellas Pharma Inc. today announced the submission of a Supplemental New Drug Application on January 31 to Japan's Ministry of Health, Labour and Welfare for PADCEV™ with KEYTRUDA ® as a ...
Medical Xpress

Olaparib and pembrolizumab combination shows early promise in molecularly selected, tumor-agnostic trial

The combination of the PARP inhibitor olaparib and the PD-1 inhibitor pembrolizumab showed initial antitumor activity with no new safety signals in a molecularly matched, tumor-agnostic trial, ...
Nature

Evolutionary Dynamics of Recombination and Sexual Reproduction

Recombination and sexual reproduction lie at the heart of evolutionary innovation, reshuffling alleles to generate genetic diversity and enabling populations to adapt to shifting environments. Meiotic ...
ascopubs.org

Association between homologous recombination deficiency (HRD) gene mutations and the efficacy of venadaparib in combination with irinotecan as third- or fourth-line treatment ...

Effect of simvastatin on PD-L1 via ILF3 to enhance CD8+ T cell-mediated ferroptosis in gastric cancer cells. Effectiveness and safety analysis of serplulimab-based regimens in patients with ...
ascopubs.org

US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated ...

The approval was based on the HRR gene-mutated (HRRm) population of TALAPRO-2, a randomized, double-blind trial that randomly assigned 1,035 patients with mCRPC to receive enzalutamide with either ...
Nanowerk

Recombinant DNA: Revolutionizing Biotechnology and Medicine

Recombinant DNA (rDNA) refers to artificial DNA molecules that are created by combining genetic material from different sources. This technology involves the insertion of DNA fragments from one ...